329 related articles for article (PubMed ID: 27916840)
1. Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response.
Davra V; Kimani SG; Calianese D; Birge RB
Cancers (Basel); 2016 Nov; 8(12):. PubMed ID: 27916840
[TBL] [Abstract][Full Text] [Related]
2. Requirement of Gamma-Carboxyglutamic Acid Modification and Phosphatidylserine Binding for the Activation of Tyro3, Axl, and Mertk Receptors by Growth Arrest-Specific 6.
Geng K; Kumar S; Kimani SG; Kholodovych V; Kasikara C; Mizuno K; Sandiford O; Rameshwar P; Kotenko SV; Birge RB
Front Immunol; 2017; 8():1521. PubMed ID: 29176978
[TBL] [Abstract][Full Text] [Related]
3. TAM Receptor Inhibition-Implications for Cancer and the Immune System.
Aehnlich P; Powell RM; Peeters MJW; Rahbech A; Thor Straten P
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801886
[TBL] [Abstract][Full Text] [Related]
4. Targeting the TAM Receptors in Leukemia.
Huey MG; Minson KA; Earp HS; DeRyckere D; Graham DK
Cancers (Basel); 2016 Nov; 8(11):. PubMed ID: 27834816
[TBL] [Abstract][Full Text] [Related]
5. TAM receptors, Phosphatidylserine, inflammation, and Cancer.
Burstyn-Cohen T; Maimon A
Cell Commun Signal; 2019 Nov; 17(1):156. PubMed ID: 31775787
[TBL] [Abstract][Full Text] [Related]
6. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Peeters MJW; Rahbech A; Thor Straten P
Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
[TBL] [Abstract][Full Text] [Related]
7. Tumour-Secreted Protein S (ProS1) Activates a Tyro3-Erk Signalling Axis and Protects Cancer Cells from Apoptosis.
Al Kafri N; Hafizi S
Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766614
[TBL] [Abstract][Full Text] [Related]
8. Post-translational modifications of the ligands: Requirement for TAM receptor activation.
Geng K
Int Rev Cell Mol Biol; 2020; 357():35-55. PubMed ID: 33234244
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of TAM tyrosine kinase receptors and ligands in endometrial carcinoma: An in silico-study.
Dilara Fatma Akin ; Özkan D
Taiwan J Obstet Gynecol; 2023 Mar; 62(2):311-324. PubMed ID: 36965901
[TBL] [Abstract][Full Text] [Related]
10. Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment.
Wang KH; Ding DC
Tzu Chi Med J; 2021; 33(3):250-256. PubMed ID: 34386362
[TBL] [Abstract][Full Text] [Related]
11. TAM Signaling in the Nervous System.
Burstyn-Cohen T; Hochberg A
Brain Plast; 2021; 7(1):33-46. PubMed ID: 34631419
[TBL] [Abstract][Full Text] [Related]
12. Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Espindola MS; Habiel DM; Narayanan R; Jones I; Coelho AL; Murray LA; Jiang D; Noble PW; Hogaboam CM
Am J Respir Crit Care Med; 2018 Jun; 197(11):1443-1456. PubMed ID: 29634284
[TBL] [Abstract][Full Text] [Related]
13. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
Yan S; Vandewalle N; De Beule N; Faict S; Maes K; De Bruyne E; Menu E; Vanderkerken K; De Veirman K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694201
[TBL] [Abstract][Full Text] [Related]
14. The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy.
Paolino M; Penninger JM
Cancers (Basel); 2016 Oct; 8(10):. PubMed ID: 27775650
[TBL] [Abstract][Full Text] [Related]
15. The first laminin G-like domain of protein S is essential for binding and activation of Tyro3 receptor and intracellular signalling.
Al Kafri N; Ahnström J; Teraz-Orosz A; Chaput L; Singh N; Villoutreix BO; Hafizi S
Biochem Biophys Rep; 2022 Jul; 30():101263. PubMed ID: 35518197
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors.
Hedrich V; Breitenecker K; Djerlek L; Ortmayr G; Mikulits W
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771611
[TBL] [Abstract][Full Text] [Related]
17. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
18. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Kasikara C; Davra V; Calianese D; Geng K; Spires TE; Quigley M; Wichroski M; Sriram G; Suarez-Lopez L; Yaffe MB; Kotenko SV; De Lorenzo MS; Birge RB
Cancer Res; 2019 May; 79(10):2669-2683. PubMed ID: 30877108
[TBL] [Abstract][Full Text] [Related]
19. Growth Arrest-Specific 6 (Gas6) and TAM Receptors in Mouse Platelets.
Uras F; Küçük B; Bingöl Özakpınar Ö; Demir AM
Turk J Haematol; 2015 Mar; 32(1):58-63. PubMed ID: 25805676
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.
Smart SK; Vasileiadi E; Wang X; DeRyckere D; Graham DK
Cancers (Basel); 2018 Nov; 10(12):. PubMed ID: 30501104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
